4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

WALTHAM, Mass. & LONDON--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec (the “Acquisition”). It is intended that the Acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the “Scheme”). Under the terms of the Acquisition, Oxford Immunotec shareholders will be entitled to receive USD 22.00 in cash for each outstanding ordina

15-12B - Oxford Immunotec Global PLC (0001586049) (Filer)

S-8 POS - Oxford Immunotec Global PLC (0001586049) (Filer)

S-8 POS - Oxford Immunotec Global PLC (0001586049) (Filer)

8-K - Oxford Immunotec Global PLC (0001586049) (Filer)

25-NSE - Oxford Immunotec Global PLC (0001586049) (Subject)

8-K/A - Oxford Immunotec Global PLC (0001586049) (Filer)

8-K - Oxford Immunotec Global PLC (0001586049) (Filer)

SC 13D - Oxford Immunotec Global PLC (0001586049) (Subject)

DEFM14A - Oxford Immunotec Global PLC (0001586049) (Filer)

PREM14A - Oxford Immunotec Global PLC (0001586049) (Filer)

OXFORD, United Kingdom and MARLBOROUGH, Mass., March 4, 2021 /PRNewswire/ -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test. T-SPOT®.COVID, a Test from Oxford Immunotec Global PLC for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection Serology does not give the full picture of the adaptive immune response to SARS-CoV-2 infe

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has worked with GC MS and MESDIA Co., Ltd. to enter into an MOU to market the research use only T-SPOT Discovery SARS-CoV-2 kit in South Korea. Under this agreement, GC MS will market/sell, MESDIA will import, and Oxford Immunotec Korea will provide overall support for the T-SPOT Discovery SARS-CoV-2 kit. Based on the Company’s T-SPOT technology, the only globally approved ELISPOT currently used clinically for the diagnosis of Tuberculosis infection; the T-SPOT Discovery SARS-CoV-2 kit is

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces an update to the configuration of the T-SPOT Discovery SARS-CoV-2 kit. The kit, for research use only, has been updated using the Company’s growing expertise of the T cell response to SARS-CoV-2 infection. The previous T-SPOT Discovery SARS-CoV-2 kit configuration included five antigen wells, each containing a mix of peptides representing target epitopes derived from the virus, with areas of high homology to endemic coronaviruses removed. Using the Company’s growing results database, it has

OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announces the launch of 100 Physicians Find, a monthly survey that takes the pulse of one hundred medical professionals on the front lines of the COVID-19 pandemic about their perspectives, experiences and needs in the face of this global health crisis. In its first installment of 100 Physicians Find, the Company reports results identifying gaps in the testing toolbox. Oxford Immunotec is sharing the results as a call for the industry to heed the need of physicians who are making critical decisions for the

OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce the start of a collaboration with Valneva. The Company will perform T cell testing on participants receiving Valneva’s inactivated whole-virus COVID-19 vaccine candidate (VLA2001) with the research use only T-SPOT Discovery SARS-CoV-2 test. The VLA2001-201 study is a randomized Phase I/II clinical study designed to evaluate the safety, tolerability and immunogenicity of an inactivated SARS-CoV-2 virus vaccine candidate in healthy subjects, the first study of its kind performed in Europe. The Company

WALTHAM, Mass. & LONDON--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec (the “Acquisition”). It is intended that the Acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the “Scheme”). Under the terms of the Acquisition, Oxford Immunotec shareholders will be entitled to receive USD 22.00 in cash for each outstanding ordina

OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce the formation and initial meeting of the Global T cell expert consortium (GTEC). The GTEC is a community of experts in T cell research, epidemiology, vaccine research and global public health. It aims to be the leading voice for T cell expertise during and beyond the current COVID-19 pandemic. The GTEC is an independent forum, with its agenda, research and associated education driven by the consortium experts, with support from Oxford Immunotec. The goal of the GTEC is to advance the frontiers

OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announced that the Company’s T-Cell Select reagent kit has been approved for use by the Ministry of Food and Drug Safety, South Korea. The T-Cell Select reagent kit is an immune cell separation reagent. It is used to automate the preparation of the cells required to run the Company’s T-SPOT.TB test, for diagnosis of TB infection, from patient blood samples. The T-Cell Select reagent kit streamlines and simplifies the T-SPOT.TB test laboratory protocol. Automation makes implementation of the T-SPOT.TB t

OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has entered into an exclusive distribution agreement with RIKEN Genesis Co., Ltd, a subsidiary of The Sysmex Corporation (Sysmex), in Japan. Under the agreement, RIKEN Genesis will exclusively distribute the T-SPOT Discovery SARS-CoV-2 kit (Research Use Only), developed by Oxford Immunotec for the detection and measurement of SARS-CoV-2 specific T cells, which may offer new insight into immunity to SARS-CoV-2 infection. Based on the company’s T-SPOT technology, the only globally approved E